NDE1 Antibody

What is NDE1 and why is it important in research?

NDE1 (Nuclear Distribution E Homolog 1) is a crucial dynein binding partner involved in centrosome functioning and chromosome separation during cell division. Research interest in NDE1 has grown due to its potential role in multiple biological processes including genomic stability and its implications in cancer and neurodevelopmental disorders. The NDE1 protein can disrupt normal centrosome function, potentially compromising spindle generation and precise chromosome separation during cell division . This disruption can lead to genomic instability, malignant transformation, and neoplastic growth proliferation, making it a significant target for cancer research . Additionally, NDE1 is of interest in neuroscience research due to its interaction with DISC1 (Disrupted in Schizophrenia 1), which is associated with psychiatric disorders .

How specific are commercially available NDE1 antibodies?

Commercial NDE1 antibodies often show cross-reactivity with NDEL1 (NDE-Like 1) due to the high sequence homology between these proteins. When tested against equivalent amounts of bacterial GST-NDE1 and GST-NDEL1 proteins, multiple commercial antibodies detected both proteins on Western blots . This cross-reactivity presents a significant challenge for researchers studying NDE1-specific functions. To address this issue, custom antibodies (such as antibodies 92 and 93 described in the literature) have been developed against specific regions of human NDE1 (amino acids 292-306 and 187-201, respectively) that demonstrate improved specificity against NDE1 without cross-reacting with NDEL1 .

What validation methods should be used for NDE1 antibodies?

To ensure proper validation of NDE1 antibodies, researchers should employ multiple complementary approaches:

• Specificity testing against recombinant proteins: Compare reactivity against purified NDE1 and NDEL1 recombinant proteins (e.g., GST-tagged) on Western blots .

• Peptide pre-absorption analysis: Pre-incubate the antibody with the immunizing peptide to confirm that signal disappearance occurs .

• Detection of overexpressed tagged-NDE1: Confirm that the antibody recognizes overexpressed tagged versions of NDE1 in cell lines (e.g., V5-tagged NDE1 in COS7 cells) .

• Endogenous protein detection: Verify that the antibody detects endogenous NDE1 at the expected molecular weight (approximately 38 kDa for common isoforms) in relevant cell lines like SH-SY5Y .

• Co-localization with known partners: Demonstrate co-localization with established NDE1 partners such as γ-tubulin or LIS1 using confocal microscopy .

What cellular localization patterns can be detected with NDE1 antibodies?

NDE1 exhibits multiple subcellular localizations that can be detected using validated antibodies:

Endogenous NDE1 is detectable at the centrosome (confirmed by γ-tubulin co-localization) in approximately 35% of NDE1-expressing cells . Additionally, punctate NDE1 staining is observed throughout the cytoplasm, and interestingly, many cells (approximately 53%) exhibit stronger NDE1 signal in the nucleus than in the cell body . This nuclear localization represents a novel finding that warrants further investigation with independently produced antibodies.

How can researchers detect different NDE1 isoforms using antibodies?

Detection of specific NDE1 isoforms requires careful antibody selection and experimental design:

• Isoform awareness: Multiple isoforms of NDE1 exist in the brain, including variations with different C-terminal sequences (e.g., NDE1-SSSC, NDE1-KMLL, NDE1-KRHS) . These isoforms have similar molecular weights (37-39 kDa) making them difficult to distinguish on standard Western blots.

• Epitope targeting: Select antibodies raised against regions that are either common to all isoforms (for total NDE1 detection) or unique to specific isoforms (for isoform-specific detection). The literature describes antibodies raised against amino acids 292-306 (antibody 92) and 187-201 (antibody 93) of human NDE1 .

• High-resolution gel systems: Employ gradient gels or other high-resolution electrophoresis systems to separate closely migrating isoforms.

• Two-dimensional electrophoresis: Combine isoelectric focusing with SDS-PAGE to separate isoforms that differ in post-translational modifications or charged amino acids.

• Isoform-specific knockdown: Validate antibody specificity by knocking down specific isoforms using targeted siRNAs and confirming selective reduction of the corresponding band.

What methods are most effective for using NDE1 antibodies in co-immunoprecipitation studies?

Effective co-immunoprecipitation (co-IP) with NDE1 antibodies requires attention to several methodological considerations:

• Antibody validation: Ensure the antibody can effectively immunoprecipitate NDE1 without interfering with protein-protein interaction domains. The literature demonstrates successful immunoprecipitation of endogenous NDE1 using antibody 93, which can co-precipitate interaction partners like LIS1 .

• Lysis conditions: Use mild lysis conditions (e.g., 1% Triton X-100 or NP-40) to preserve protein complexes. Consider testing multiple lysis buffers as NDE1 interactions may have different stability requirements.

• Cross-linking considerations: For transient or weak interactions, consider using membrane-permeable crosslinking agents before lysis.

• Control experiments: Include appropriate controls:

  • IgG control to identify non-specific binding

  • Input samples to confirm presence of proteins before IP

  • Reciprocal IP (using antibodies against interaction partners)

• Validation of direct interactions: To distinguish direct from indirect interactions within complexes, complement co-IP studies with in vitro binding assays using purified or in vitro transcribed/translated proteins. This approach has been used to confirm direct self-association of NDE1 .

How can NDE1 antibodies be used to investigate protein multimerization and complex formation?

NDE1 participates in complex protein interactions including self-association and hetero-complex formation with NDEL1. Antibodies can be valuable tools for studying these complexes:

• Detection of NDE1 multimers: NDE1 can self-associate to form multimers, similar to NDEL1 . This can be investigated using:

  • Co-IP of differently tagged NDE1 constructs (e.g., V5-NDE1 and GFP-NDE1)

  • In vitro binding assays with in vitro transcribed/translated NDE1

  • Size exclusion chromatography followed by Western blotting with NDE1 antibodies

• NDE1-NDEL1 complex detection: NDE1 can complex with NDEL1, potentially through domains similar to those involved in NDEL1 self-association. This has been demonstrated through:

  • Co-IP of tagged constructs (GFP-NDE1 and V5-NDEL1)

  • IP of endogenous NDE1 from SH-SY5Y lysates, which co-precipitates 38 kDa NDEL1

• Interaction domain mapping: Antibodies recognizing different epitopes can help determine which domains are accessible in complexes versus those involved in binding interfaces.

• Structural studies: Immunolabeling combined with techniques like electron microscopy can provide insights into the arrangement of proteins within complexes.

What are the best practices for using NDE1 antibodies in cancer research?

NDE1 has emerged as a potential biomarker and therapeutic target in multiple cancer types. When using NDE1 antibodies in cancer research, consider these best practices:

What considerations are important when studying NDE1-DISC1 interactions with antibodies?

The interaction between NDE1 and DISC1 (Disrupted in Schizophrenia 1) is of significant interest in neuropsychiatric research. Key considerations include:

• Multiple interaction sites: NDE1 binds directly to multiple isoforms of DISC1 . Ensure antibodies do not interfere with interaction domains.

• Isoform awareness: Both NDE1 and DISC1 exist as multiple isoforms that may interact differently. Document which specific isoforms are being studied.

• Competition with NDEL1: Since NDEL1 also interacts with DISC1 and can form complexes with NDE1, consider the possibility of competitive or cooperative binding in the experimental design.

• Subcellular localization: The interaction may be compartment-specific, potentially involving centrosomal, cytoplasmic, or even nuclear localization. Use immunofluorescence with confocal microscopy to determine co-localization patterns.

• Validation approaches: Use multiple methods to confirm interactions:

  • Co-IP with antibodies against different epitopes

  • Proximity ligation assay for detecting interactions in situ

  • FRET or BiFC for live-cell interaction studies

What are the optimal conditions for Western blot analysis with NDE1 antibodies?

Optimizing Western blot conditions for NDE1 detection requires attention to several technical factors:

• Sample preparation:

  • Use protease inhibitors in lysis buffers to prevent degradation

  • Consider phosphatase inhibitors if studying phosphorylated forms

  • Optimal lysis buffer composition may depend on subcellular compartment (e.g., nuclear extraction protocols for nuclear NDE1)

• Gel percentage:

  • 10-12% gels are typically suitable for resolving NDE1 (38 kDa)

  • Consider gradient gels (4-20%) when attempting to resolve multiple isoforms

• Transfer conditions:

  • Semi-dry or wet transfer systems are both suitable

  • Consider methanol concentration in transfer buffer (10-20%)

  • Transfer time: 1 hour at 100V or overnight at 30V

• Blocking conditions:

  • 5% non-fat dry milk in TBST is typically effective

  • For phospho-specific detection, 3-5% BSA may be preferred

• Antibody dilution ranges:

  • Primary: 1:500 to 1:2000 depending on antibody (optimize for each)

  • Secondary: 1:5000 to 1:10000 HRP-conjugated antibodies

• Controls:

  • Positive control: lysate from cells known to express NDE1 (e.g., SH-SY5Y)

  • Negative control: lysate from cells with NDE1 knockdown

  • Loading control: typically β-actin, GAPDH, or α-tubulin

How can researchers distinguish between NDE1 and NDEL1 in experimental systems?

Distinguishing NDE1 from the highly homologous NDEL1 requires careful experimental design:

• Selective antibodies: Use antibodies raised against non-conserved regions. The literature describes antibodies 92 and 93 raised against amino acids 292-306 and 187-201 of human NDE1, which can specifically detect NDE1 without cross-reacting with NDEL1 .

• Antibody validation: Validate specificity by testing against equivalent amounts of recombinant NDE1 and NDEL1 proteins (e.g., GST-tagged) on Western blots .

• Isoform-specific knockdown: Use siRNA or shRNA targeting unique regions of NDE1 or NDEL1 to confirm antibody specificity.

• Mass spectrometry: For definitive identification, consider immunoprecipitation followed by mass spectrometry to identify peptides unique to NDE1 versus NDEL1.

• Expression pattern analysis: In cases where tissue or cellular distribution differs between NDE1 and NDEL1, use this information to aid interpretation of results.

What immunohistochemistry protocols work best with NDE1 antibodies?

For optimal immunohistochemistry (IHC) results with NDE1 antibodies, consider these protocol recommendations:

• Fixation methods:

  • 4% paraformaldehyde (PFA) for 24-48 hours is generally suitable

  • For some epitopes, brief fixation (10-15 minutes) with methanol at -20°C may better preserve antigenicity

• Antigen retrieval:

  • Heat-induced epitope retrieval: 10mM citrate buffer (pH 6.0) for 20 minutes

  • For some antibodies, EDTA buffer (pH 8.0) may yield better results

  • Test both methods to determine optimal conditions for specific antibodies

• Blocking and permeabilization:

  • Block with 5-10% normal serum (species of secondary antibody) with 0.1-0.3% Triton X-100

  • For cell lines, 0.1% Triton X-100 for 10 minutes is typically sufficient for permeabilization

• Antibody incubation:

  • Primary: Overnight at 4°C at optimized dilution (typically 1:100 to 1:500)

  • Secondary: 1-2 hours at room temperature (typically 1:500 dilution)

• Controls:

  • Peptide competition control (pre-absorb antibody with immunizing peptide)

  • Tissue from NDE1 knockout models or cells with NDE1 knockdown

  • Known positive control tissues with established NDE1 expression

• Co-localization markers:

  • γ-tubulin for centrosomal localization

  • LIS1 as an interaction partner

  • Nuclear markers (e.g., DAPI) to assess nuclear localization

How can NDE1 antibodies be used to study its role in immune regulation in cancer?

Recent research has identified relationships between NDE1 and immune-related parameters in cancer, suggesting new applications for NDE1 antibodies:

• Immune checkpoint correlation: NDE1 expression correlates with multiple immune checkpoint genes . Multiplex immunofluorescence combining NDE1 antibodies with antibodies against immune checkpoint proteins can reveal spatial relationships in the tumor microenvironment.

• Immune cell infiltration: NDE1 is associated with immune cell infiltration patterns . Using NDE1 antibodies alongside immune cell markers can help characterize the relationship between NDE1 expression and the immune landscape.

• Tumor immune subtypes: NDE1 expression is linked to specific tumor immune subtypes . IHC with NDE1 antibodies may help categorize tumors into immunological subgroups.

• Immunotherapy response prediction: NDE1 may affect immunotherapy efficacy in different cancer types . Retrospective studies using NDE1 antibodies on tissues from immunotherapy responders versus non-responders could identify predictive patterns.

• Tumor purity assessment: The relationship between tumor purity and NDE1 expression levels suggests applications in characterizing tumor heterogeneity.

What are the current challenges in using NDE1 antibodies for studying neurodevelopmental disorders?

NDE1's interaction with DISC1, which is associated with schizophrenia and related disorders , suggests potential roles in neurodevelopmental processes. Challenges include:

• Isoform complexity: Multiple isoforms of both NDE1 and DISC1 exist in the brain , requiring antibodies that can discriminate between these variants or detect specific interaction combinations.

• Cell type specificity: Different neural cell types may express different NDE1 isoforms or exhibit different interaction patterns, necessitating single-cell or cell-type-specific analyses.

• Developmental regulation: Expression patterns and interactions may change throughout development, requiring careful staging of samples and developmental analyses.

• Subcellular localization: The novel nuclear localization observed for NDE1 adds complexity to understanding its function in neural cells, requiring subcellular fractionation approaches and high-resolution imaging.

• Multiprotein complexes: NDE1 participates in complexes with multiple partners including NDEL1, LIS1, and DISC1 . Studying these complex interactions requires specialized approaches such as BioID or proximity labeling methods.

How can researchers integrate NDE1 antibody studies with genomic and transcriptomic data?

Integrating protein-level data from NDE1 antibody studies with genomic and transcriptomic analyses creates more comprehensive understanding:

• Expression correlation: Compare NDE1 protein levels (by Western blot or IHC) with mRNA expression data to identify post-transcriptional regulation mechanisms.

• Mutation impact assessment: For samples with known NDE1 mutations or variants, use antibodies to determine effects on protein expression, localization, or interaction patterns.

• Isoform verification: Use antibodies specific to predicted isoforms to validate alternative splicing events identified in RNA-seq data.

• Multi-omics integration: Combine NDE1 antibody data with:

  • DNA methylation data (NDE1 has been studied in relation to DNA methylation in cancer )

  • m6A mRNA modification data

  • ceRNA network analysis

• Functional validation: Use NDE1 antibodies to confirm protein-level changes following genetic manipulation (e.g., CRISPR editing, siRNA) and correlate with transcriptional changes measured by RNA-seq.